colitis semaglutide Patients with stable inflammatory bowel disease (IBD) and comorbid obesity and/or diabetes who started GLP-1 receptor agonists (semaglutide or tirzepatide) alongside ongoing treatment did not have a lower risk for the relapse GLP-1s and Ulcerative Colitis: Safety

doi: 10.3389/fpsyt.2022.1002828 Received 25 July 2022 Accepted 10 October 2022 Published 15 November 2022 Volume 13 - 2022 Edited by Bharathi Gadad, Texas Tech University Health Sciences Center El Paso, United States Reviewed by Federica Ferrari, University of Pavia, Italy

Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation, which typically diminish over time with dose titration

The Science Behind the Brightening

10.3389/fphar.2022.842879 6 HeY.FuQ.SunM.QianY.LiangY.ZhangJ.et al (2022)

Dengan pemakaian nature e white secara rutin, kulitmu akan tampak lebih halus dan pastinya jadi lebih percaya diri